Key result
In heart failure patients with central sympathetic overactivation, a lower beta-blocker dose was associated with a increased risk of cardiovascular events.
Why the study?
Does the interaction between beta-blocker dose and sympathetic nerve activity affect cardiovascular outcomes in patients with systolic heart failure?
Cohort (n=133)
No
Does the interaction between beta-blocker dose and sympathetic nerve activity affect cardiovascular outcomes in patients with systolic heart failure?
Higher beta-blocker doses may be particularly necessary to prevent cardiovascular events in heart failure patients with central sympathetic overactivation.
Answers are grounded in this paper and cite their sources.
Supports higher beta-blocker doses in HF with sympathetic overactivation; hypothesis-generating and requires prospective validation.
BACKGROUND: Although both β-blocker dose (BBD) and sympathetic activity efferent drive are associated with prognosis in chronic heart failure (HF), little is known about the prognostic value of the interaction between them. METHODS AND RESULTS: Potential prognostic variables including resting muscle sympathetic nerve activity (MSNA) were investigated in 133 patients with HF (ejection fraction [EF] <0.45). BBD was normalized to therapeutically equivalent doses of carvedilol. Primary cardiovascular endpoints included cardiovascular death and HF hospitalization. Predictors for outcomes were assessed on univariate, multivariate, and Kaplan-Meier analysis. EF was followed for 9 months after MSNA measurement in 102 patients. During the 1,419±824-day follow-up period, 24 patients died (sudden death, n=10; progressive HF, n=14). On multivariate Cox proportional hazard analysis, higher MSNA (P=0.037; HR, 2.01) and lower BBD (<5.0 mg/day; P=0.041; HR, 1.94) were independent predictors of cardiovascular events. Patients were divided into higher MSNA (≥64 bursts/100 beats) and lower MSNA groups. Although lower BBD remained an independent predictor in patients with higher MSNA, BBD was not statistically significant in patients with lower MSNA on univariate analysis. Additionally, there was a lower EF change in patients with lower BBD and higher MSNA. CONCLUSIONS: Higher BBD might be necessary to avoid cardiovascular events in HF patients with central sympathetic overactivation. (Circ J 2016; 80: 2149-2154).
No takes yet. Share an insight, caveat, or question.
Joho et al. (2016) conducted a cohort in Systolic Heart Failure (n=133). Lower beta-blocker dose (<5.0 mg/day carvedilol equivalent) vs. Higher beta-blocker dose (≥5.0 mg/day carvedilol equivalent) was evaluated on Cardiovascular death and heart failure hospitalization (HR 2.41, 95% CI 1.06-5.74, p=0.035). In heart failure patients with central sympathetic overactivation, a lower beta-blocker dose was associated with a increased risk of cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: